featured-image

, /PRNewswire/ -- Kinomica Ltd., a developer of KScan® precision oncology diagnostics, today announces that it will be presenting data on a multi-drug biomarker signature for accurately predicting best first-line treatments in newly-diagnosed acute myeloid leukemia patients at the American Society of Clinical Oncology (ASCO) annual meeting, which will be held – , in "AML is a heterogeneous malignancy with poor prognosis. Several treatments are approved for AML, but clinical trials have shown that current stratification approaches to determine patients' eligibility produce false positives and negatives," said Arran Dokal PhD, CTO of Kinomica.

"Here, we used phosphoproteomics to build signatures that accurately predict which of the approved therapies venetoclax plus azacitidine, intensive chemotherapy (IC), or IC plus midostaurin may be more efficacious for a given patient." Details of the poster presentation are as follow: : Multi-drug algorithm to accurately predict best first-line treatments in newly-diagnosed acute myeloid leukemia (AML) : at Barts Cancer Institute : , , , , , , Federico Pedicona , Nazrath Nawaz , , , , , Sayantanee Dutta , , , Gabriel Ghiaur , , , , Arran David Dokal : Barts Cancer Institute, Princess Margaret Cancer Centre, Johns Hopkins University, Medical University of Graz, Kinomica Ltd : Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant : , : 84 : 6525 The Abstract is available on the ASCO online itinerary planner ..



Back to Health Page